GlassScriptPhysician profile
Robert R Reagle
NPI 1619959509
$11,978.04
in general payments reported to CMS, 2019-2025
41 companies · $25.88 in 2025
The $25.88 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,557 · 2020: $1,298 · 2021: $2,373 · 2022: $2,324 · 2023: $2,822 · 2024: $577 · 2025: $25.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.88 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,206.89 | 2019-2024 | Breztri, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $1,794.38 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $1,545.24 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,187.42 | 2019-2024 | Spiriva Respimat, Ofev, Stiolto Respimat |
| Harmony Biosciences LLC | $884.05 | 2020-2024 | Wakix |
| Mylan Specialty L.P. | $516.22 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $432.98 | 2020-2024 | Glassia |
| Regeneron Healthcare Solutions, INC. | $424.82 | 2019-2024 | Dupixent |
| Grifols USA, LLC | $309.07 | 2019-2023 | Prolastin-C Liquid |
| Alexion Pharmaceuticals, INC. | $255.31 | 2019-2023 | Ultomiris |
| Genzyme Corporation | $228.77 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $215.11 | 2019-2020 | |
| Philips North America LLC | $203.82 | 2019-2025 | Vest Therapy Und |
| Mallinckrodt Enterprises LLC | $184.05 | 2019 | |
| United Therapeutics Corporation | $163.26 | 2022-2024 | Tyvaso |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $157.92 | 2021-2024 | Smartvest |
| Genentech USA, INC. | $130.83 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $113.56 | 2019-2021 | |
| Pulmonx Corporation | $98.53 | 2020-2023 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Shire North American Group INC | $89.90 | 2019 | |
| Ani Pharmaceuticals, INC. | $70.79 | 2023-2024 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $70.47 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $69.36 | 2020-2022 | |
| Circassia INC. | $66.09 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $63.00 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $60.17 | 2021-2022 | |
| Inspire Medical Systems, INC. | $57.47 | 2023-2024 | Inspire |
| Amgen INC. | $53.21 | 2022 | |
| Arbor Pharmaceuticals, INC. | $46.07 | 2019-2020 | |
| Advanced Respiratory, INC | $44.79 | 2020-2021 | |
| Axsome Therapeutics, INC. | $32.97 | 2023 | Sunosi |
| Resmed Corp | $27.79 | 2019 | |
| Abbvie INC. | $25.22 | 2023 | |
| Itamar Medical INC | $24.97 | 2024 | Watchpatone |
| Avadel Cns Pharmaceuticals, LLC | $23.52 | 2024 | Lumryz |
| Paratek Pharmaceuticals, INC. | $19.08 | 2023 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $18.54 | 2020 | |
| La Jolla Pharmaceutical Company | $17.60 | 2019 | |
| Covis Pharma Gmbh | $17.21 | 2023 | |
| Pfizer INC. | $14.09 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.